Skip to content

#神经

Today 0 items
Oct 14Wed
  1. nature.com46

    Can GLP-1s heal the brain? Obesity drugs get a makeover for addiction and depression

    Eli Lilly presented the first clinical results of brenipatide, a GLP-1 and GIP mimic related to tirzepatide, for alcohol use disorder at the Psych Congress in New Orleans; its half-life is 9–12 days versus 5–7 days for approved GLP-1 drugs. Kariya Pharmaceuticals shared early clinical results of the GLP-1 compound KP405 for Parkinson's disease, and Baseline Therapeutics plans phase III trials of BT-001 for alcohol use disorder starting in early 2027. Academic trials, including a 2025 semaglutide study in alcohol use disorder, have shown reduced craving and heavy drinking, encouraging industry interest in GLP-1 therapies for addiction and other brain disorders.

  2. jamanetwork.com77

    The 2026 Albert Lasker Basic Medical Research Award

    Emmanuel Mignot and Masashi Yanagisawa, winners of the 2026 Albert Lasker Basic Medical Research Award, identified the brain peptide orexin and established its role in sleep regulation. Their work linked orexin deficiency to narcolepsy. The Perspective traces how the discovery advanced understanding of the sleep disorder.

    Why it matters: Lasker Award honors the discovery of orexin and its link to narcolepsy.

Oct 13Tue
  1. nature.com69

    Engrafting human cortical organoids

    Kaganovsky and colleagues, writing in Nature, describe xenocortication, a method for integrating human cortical organoids into the mouse brain. They transplanted human iPSC-derived cortical organoids into the cortical cavity of neonatal immunodeficient apallial mice, in which most of the neocortex and hippocampus had been genetically depleted. MRI showed the grafts grew approximately 4.7-fold between 2 and 3 months after transplantation and made up nearly 92% of the combined cortical tissue volume.

    Why it matters: The graft growth data show a new route to larger, better integrated human brain organoid models in rodents.

Oct 11Sun
  1. Lancet40

    Migraine.

    Migraine is a chronic neurovascular disorder marked by recurrent moderate-to-severe head pain with disabling symptoms including aura, nausea, vomiting, phonophobia and photophobia. Its pathogenesis involves genetic and epigenetic factors across complex neurosensory and neurovascular networks. Decades of research have driven mechanism-based therapies that are transforming clinical practice and improving patients' lives.

    Why it matters: Reviews migraine pathogenesis and the mechanism-based therapies now changing clinical practice.

  2. medicalxpress.com63

    Physical activity weakens link between genetic risk and depression severity, long-term data suggest

    Researchers at the University of Texas at San Antonio analyzed data from 23,517 adults in the NIH All of Us Research Program, combining depression polygenic risk scores, electronic health records and long-term Fitbit measurements averaging about 1.6 years per participant. Published in Nature Mental Health, the study found greater physical activity was associated with lower depression severity, with a stronger association among those with higher genetic vulnerability. The team aims to use such findings to develop personalized exercise recommendations for depression prevention and management.

    Why it matters: Long-term wearable data show physical activity buffers genetic risk of depression severity, informing precision-medicine approaches.

Oct 9Fri
  1. medicalxpress.com51

    Common herbal sleep aid shows signs of addictive potential

    University of Connecticut researchers led by Steven Kinsey and Olivia Vanegas found that cannabinol (CBN), a cannabis-derived ingredient in over-the-counter sleep products, produced tolerance and withdrawal signs in mice given the compound twice daily for three days. Mice trained to recognize THC's effects responded identically to CBN, and CBN also weakened immune defense during a simulated bacterial challenge at non-psychoactive anti-inflammatory doses. The study appears in the November 2026 issue of Drug and Alcohol Dependence, and the authors say human research on dosing and long-term effects is still needed.

Oct 8Thu
  1. nature.com53

    Editorial Expression of Concern: Maternal gut bacteria promote neurodevelopmental abnormalities in mouse offspring

    Nature has issued an Editorial Expression of Concern on the 2017 paper by Sangdoo Kim, Hyunju Kim and colleagues, "Maternal gut bacteria promote neurodevelopmental abnormalities in mouse offspring," first published online on 13 September 2017. The notice is signed by the journal's editors, with correspondence directed to Gloria B. Choi of MIT or Jun R. Huh, now at Harvard Medical School and Brigham and Women's Hospital.

  2. nature.com40

    Nobel prizes 2026: brain switches, ‘ghost’ particle hunter, and ‘the chemistry of life’

    The 2026 Nobel Prizes in science honoured work on a brain 'switch' that controls neurons with light in medicine, the detection of cosmic neutrinos in physics, and the emergence of 'handed' organic molecules in chemistry. The medicine award was described as overdue. Nature's podcast of 7 October 2026 also covered research on the ancient human gut microbiome tracing early human journeys.

Oct 7Wed
  1. nature.com40

    Can your brain grow new neurons? How researchers are solving a century-old puzzle

    Whether the adult human brain generates new neurons remains contested decades after the debate began, with leading neuroscientists including Arturo Alvarez-Buylla, Rusty Gage, Hongjun Song and Gerd Kempermann split over the evidence. A 1998 Nature Medicine study of brain tissue from five cancer patients given BrdU found new neurons in the hippocampus, but a later paper from Shawn Sorrells challenged the finding. The field is now shifting toward consolidating methods and asking what new neurons do and whether they can treat neurodegeneration.

  2. Science40

    Sex-specific mechanisms of chronic pain.

    A review in Science synthesizes recent findings on sex-specific mechanisms of chronic pain, a field transformed after sex became a required biological variable in research in 2016. It covers visceral and somatic pain, including irritable bowel syndrome, endometriosis and fibromyalgia, and points to sex hormones, immune-neural cross-talk, the gut microbiome and endogenous analgesic circuits as distinct pathways in females. The work aims to support mechanism-based precision therapeutics.

  3. jamanetwork.com51

    Defining Amyloid Positivity on the Centiloid Scale

    A JAMA piece examines how amyloid PET imaging defines amyloid positivity on the Centiloid scale in Alzheimer disease research and clinical care. Amyloid PET has shaped understanding of disease natural history, guided patient selection and served as a trial outcome measure, supporting FDA approval of amyloid-targeting therapies as the first disease-modifying class. Clinically it aids diagnosis in mild cognitive impairment and confirms plaques before treatment.

Oct 6Tue
  1. nature.com60

    Brain organoids grafted into cortex-free mice will advance human brain research

    Kaganovsky et al. report in Nature an engraftment model in which human stem-cell-derived brain organoids are transplanted into living mice. The approach produces neurons that cannot be obtained in vitro and may let researchers connect brain injury to behaviour, overcoming limits of organoids that cannot mature, lack interaction with other brain structures and give no behavioural output. Marty G. Yang and Aparna Bhaduri of UCLA discuss the work in a News and Views piece.

    Why it matters: Human organoids transplanted into mice yield neurons and behavioural readouts unavailable in vitro.

  2. nature.com40

    Daily briefing: Medicine Nobel prize goes to optogenetics

    Karl Deisseroth, Peter Hegemann and Georg Nagel have won the 2026 Nobel Prize in Physiology or Medicine, awarded on 5 October, for developing optogenetics, a technology that lets researchers control neurons with pulses of light. Hegemann and Nagel discovered channelrhodopsin in a light-seeking alga, and Deisseroth later inserted its gene into neurons to make them fire. Direct medical applications, such as partial vision restoration in retinitis pigmentosa, have emerged in recent years.

  3. biocentury.com80

    Nobel Prize for optogenetics arrives as first therapy nears FDA decision

    Karl Deisseroth, Peter Hegemann and Georg Nagel share the 2026 Nobel Prize in Physiology or Medicine for discoveries concerning light-gated ion channels and optogenetics. FDA is due to decide by mid-2027 whether the first optogenetic therapy, a retinal gene therapy, reaches the market. Nanoscope leads direct therapeutic applications of the technology, while MapLight uses it to guide psychiatric drug discovery.

    Why it matters: Nobel recognition coincides with the first optogenetic therapy approaching an FDA decision.

  4. statnews.com64

    STAT+: Nobel-winning optogenetics research has led to experimental treatments for blindness and Alzheimer’s

    Karl Deisseroth of Stanford University and the Howard Hughes Medical Institute won the 2026 Nobel Prize for Medicine on Monday, shared with German colleagues Peter Hegemann and Georg Nagel, for developing optogenetics tools that can target individual cells with millisecond speed. The work has led to experimental treatments for blindness and Alzheimer's. Deisseroth said the field's challenge was building tools matching the brain's complexity and precision.

  5. nature.com53

    ‘What took them so long?’ This year’s medicine Nobel winner is overdue

    The 2026 Nobel Prize in Physiology or Medicine goes to Karl Deisseroth, Peter Hegemann and Georg Nagel for optogenetics, whose foundational work dates to the early 2000s. Neuroscientists had anticipated the award for years; optogenetics won the Brain Prize in 2013, which also recognized Edward Boyden, Gero Miesenböck and Ernst Bamburg. Michael Häusser suggests the Nobel Committee waited because direct applications to human disease emerged only in the past few years.

Oct 5Mon
  1. nature.com92

    Medicine Nobel awarded for brain ‘switch’ that controls neurons with light

    Karl Deisseroth of Stanford University, Peter Hegemann of Humboldt University of Berlin and Georg Nagel of the University of Würzburg have won the 2026 Nobel Prize in Physiology or Medicine for their discoveries in optogenetics. Working at the Max Planck Institute of Biochemistry in the early 2000s, Hegemann and Nagel discovered channelrhodopsin, a light-sensitive protein from the alga Chlamydomonas reinhardtii; Deisseroth and colleagues then showed the gene could make rat neurons fire in response to light. The technique lets researchers control individual neurons and brain circuits to study effects on behaviour.

    Why it matters: The Nobel Prize in Physiology or Medicine recognizes optogenetics, a core tool in neuroscience and biomedical research.

Oct 3Sat
  1. medicalxpress.com43

    How sex chromosomes influence lifelong health beyond determining biological sex

    A review published in Science, co-led by Dr. Dan Theodorescu of the University of Arizona Cancer Center and Dr. Dena B. Dubal of UC San Francisco, argues that X and Y chromosome genes shape disease risk, progression and treatment response in aging, cancer, neurological conditions, immunity and cardiometabolic disease, beyond the effects of sex hormones. The review links loss of the X chromosome in women to higher leukemia risk and loss of the Y in men to cancers, heart disease, severe infections and Alzheimer's disease. It grew out of the 2025 National Institute on Aging Workshop and calls for sex-aware clinical trial design and sex-tailored diagnostics and treatment.

Sep 28Mon
  1. cell.com50

    The wu wei of brain metastases: When the gift of a pause is also a vulnerability

    García-Gómez et al. show that brain-seeding cancer cells enter an MXD4-dependent proliferative pause that restrains MYC and activates protective stress responses, allowing survival under stress before metastatic outgrowth. The pause represents a vulnerability that could be targeted to eradicate micrometastases before clinical relapse. The work appears in Cancer Cell.

    Why it matters: Identifies a targetable survival mechanism in dormant brain metastases before relapse.

Sep 18Fri
  1. Nature51

    Inflection points and transitions in Alzheimer's disease.

    Researchers propose that Alzheimer's disease does not progress as a linear cascade from amyloid-β accumulation to Tau pathology and neurodegeneration, but through discrete molecular, cellular and network phases organized around biological inflection points. At these thresholds, stress-driven loss of homeostasis produces qualitative shifts in cellular behavior, and altered tissue states spread as a mosaic across the brain. The framework, published in Nature, identifies amyloid-associated Tau phosphorylation as a pivotal inflection point and reframes Alzheimer's as a disorder shaped by biological thresholds, timing and erosion of homeostatic resilience.

    Why it matters: A Nature paper reframes Alzheimer's disease progression around biological inflection points, with implications for how pathology and symptoms are understood.

Aug 21Fri
Aug 16Sun
  1. BMJ49

    Evidence based interventions for bipolar disorder across phases and age groups: living umbrella review, evaluation, analysis, and communication hub (U-REACH) project.

    A BMJ living umbrella review (U-REACH) evaluated evidence-based treatments for bipolar disorder across mood phases and age groups, drawing on 77 systematic reviews and 2510 meta-analyses with GRADE certainty ratings. It identifies effective interventions for bipolar depression, mania and maintenance in adults versus children and adolescents, and offers results through the open access EBI-BD platform (https://ebibd-database.org). The review may be updated within two years as new evidence emerges.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org